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Abstract
Background: Community acquired pneumonia is a major cause of morbidity and mortality. The association
between serum phosphorus levels on admission and the outcome of patients with community acquired
pneumonia has not been widely examined. We aimed to investigate the prognostic value of serum phosphorus
levels on admission on the 30- day mortality.
Methods: The cohort included patients of 18 years old or older who were diagnosed with community acquired
pneumonia between 2006 and 2012. Patients were retrospectively analyzed to identify risk factors for a primary
endpoint of 30-day mortality. Binary logistic regression analysis was used for the calculation of the odds ratios (OR)
and p values in bivariate and multivariate analysis to identify association between patients’ characteristic and 30-day
mortality.
Results: The cohort included 3894 patients. In multivariate regression analysis, variables associated with increased
risk of 30-day mortality included: age >80 years, increased CURB-65 score, RDW >15, hypernatremia >150 mmol/l,
hypoalbuminemia <2 gr/dl and abnormal levels of phosphorus. Levels of <1.5 mg/dl and >4.5 mg/dl were
significantly associated with excess 30-day mortality, 38 % (OR 2.9, CI 1.8-4.9, P = 0.001) and 39 % (OR 3.4, CI 2.7-4.2,
P = 0.001), respectively. Phosphorus levels within the upper normal limits (4-4.5 mg/dl) were associated with higher
mortality rates compared to levels between 1.5-3.5 mg/dl, the reference group, 24 % (OR 1.9, CI 1.5-2.4, P = 0.001).
Conclusions: Abnormal phosphorus levels on admission are associated with increased mortality rates among
patients hospitalized with Community acquired pneumonia.
Background
Community acquired pneumonia (CAP) is among the
leading causes of mortality and severe morbidity especially
among elderly population. Despite the efficacy of modern
antibiotic treatment, it still ranks as the sixth most com-
mon cause of death [1–3]. Prognostic scores, like the
CURB65 score and the Pneumonia Patient Outcomes Re-
search Team score, were developed to estimate the risk of
adverse outcome in patients treated in emergency rooms
in an attempt to determine who is at risk for an adverse
outcome, and therefore should be hospitalized [4, 5].
Phosphorus, as an essential component in the ATP
molecule, plays a central role in the energy production .
Serum phosphorus level disturbances in patients with
pneumonia have been reported [6–9]. Hypophosphate-
mia is detected in 2-3 % of the patients hospitalized with
medical illness [10–12]. Commonly reported etiologies
for hypophosphatemia include alcohol abuse and with-
drawal, diabetic ketoacidosis, nutritional recovery, alka-
lotic states, accelerated erythropoiesis and gram negative
sepsis [13–19]. Many drugs have also been reported to
cause hypophosphatemia, the most common being
methylprednisolone, epinephrine, albumin, terbutaline,
theophylline, and diethylsilbesterol [20].
Hypophosphatemia is known to play an essential role in
impaired chemotaxis, phagocytosis, and bactericidal activ-
ity of macrophages [21]. Hypophosphtemia can lead to
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ATP depletion, a shift from oxidative phosphrylation
toward glycolysis, and subsequently, organ dysfunction
.and, especially, muscle weakness. Fisher et al found hypo-
phosphatemia to be associated with longer hospital stay,
but not with higher mortality in patients with respiratory
illness [7]. Sankaran et al, on the other hand, reported that
hypophosphatemic patients with pneumonia had longer
hospital stay and higher mortality when compared with
normophosphatemic patients [6].
In contrast to hypophosphatemia, the association be-
tween hyperphosphatemia and pneumonia has not been
widely studied.Severe hyperphosphtemia may result in
hypocalcemia which can cause tetany and pulmonary
calcification. Saldias et al showed that hyperphosphatemia
on admission represents a prognostic factor for in-hospital
mortality in elderly patients with community acquired
pneumonia [9].
In this cohort study, we aimed to examine the predictive
prognostic value of serum phosphorus level on admission
on the 30-day mortality in patients with community
acquired pneumonia.
Methods
Patients aged 18 years old or older who were diagnosed
with CAP and admitted to Rambam Health Care Campus,
a tertiary medical center, between 1 January, 2006 and 31
December, 2012 were retrospectively and consecutively an-
alyzed to identify risk factors for 30-day mortality. CAP was
defined as pneumonia identified within the first 48 hours of
hospitalization. The diagnosis of pneumonia was confirmed
when the patient fulfilled the criteria suggested by Fang
[22]. These criteria are as follows: a) infiltrate in a chest x-
ray taken on admission; b) the presence of one or more
major findings (cough, mucopurulent or hemoptic expec-
toration, axillary temperature of over 37.8 °C); or c) at least
two minor findings (pleuritic chest pain, dyspnea, decreased
level of consciousness, lung tissue condensation observed
in the physical lung examination, or a white blood count of
over 12 000/mL). Protocol for treatment of CAP included
either a combination of Ceftriaxone and Azithromycin or
Levofloxacin as monotherapy. Data were collected from the
Prometheus, an integrated computer system for handling
patients’ medical records. The 30-day mortality data were
Table 1 Bivariate analysis of patients’ characteristics associated with 30-day mortality
Clinical RISK Factors 30 day-mortality P-value OR 95 % CI
Number % Number %
3876 100 % 674 17 %
Gender Female 1664 43 % 282 17 % Ref.
Male 2212 57 % 392 18 % .529 1.056 .892 1.249
Age <45 271 7 % 13 5 % .000 Ref.
45-54 209 5 % 12 6 % .252 1.490 .753 2.947
55-64 356 9 % 30 8 % .001 2.611 1.479 4.610
65-74 579 15 % 74 13 % .000 3.187 1.876 5.416
75-84 1016 26 % 163 16 % .000 5.387 3.247 8.936
≥85 1445 37 % 382 26 % .000 8.864 5.326 14.753
Year 2006-2008 1730 45 % 289 17 % .230 Ref.
2009-2010 1058 27 % 202 19 % .109 1.177 .965 1.435
2011-2012 1088 28 % 183 17 % .937 1.008 .823 1.235
Charson’s No illnesses 599 15.4 % 57 9.5 % .000 1
Index 1 616 15.8 % 102 16.6 % .000 2.511 1.625 3.882
2 612 15.7 % 138 22.5 % .000 3.361 2.203 5.129
3-4 1105 28.4 % 326 29.5 % .000 4.983 3.377 7.355
5-7 723 18.6 % 245 33.9 % .000 5.291 3.541 7.906
8+ 239 6.1 % 108 45.2 % .000 8.678 5.522 13.637
CURB-65 0 589 15 % 11 2 % .000 Ref.
1 881 23 % 76 9 % .000 4.961 2.613 9.420
2 1286 33 % 192 15 % .000 9.222 4.981 17.073
3 826 21 % 257 31 % .000 23.733 12.838 43.875
4 263 7 % 120 46 % .000 44.094 23.157 83.959
5 31 1 % 18 58 % .000 72.755 27.708 184.387
Abbreviations: OR Odds Ratio, CI Confidence Interval, Ref. Reference
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Table 2 Bivariate analysis of laboratory parameters associated with 30-day mortality
30 day- mortality P-Value OR 95 % CI
Parameter Number % N %
3,876 100 % 674 17 %
BUN (mg/dL) <20 2754 71 % 298 11 % .000 Ref.
BUN (mg/dL) 20-39 485 13 % 134 28 % .000 3.15 2.494 3.970
BUN (mg/dL) 40-59 382 10 % 117 31 % .000 3.64 2.838 4.666
BUN (mg/dL) ≥60 255 7 % 125 49 % .000 7.92 6.029 10.416
Creatinine (mg/dL) 0.9- 1.29 2258 58 % 288 13 % .000 Ref.
Creatinine (mg/dL) 0.1- 0.9 142 4 % 27 19 % .034 1.606 1.037 2.486
Creatinine (mg/dL) 1.3-1.49 545 14 % 95 17 % .004 1.444 1.121 1.861
Creatinine (mg/dL) 1.5-1.9 455 12 % 106 23 % .000 2.078 1.618 2.668
Creatinine (mg/dL) ≥2 476 12 % 158 33 % .000 3.399 2.708 4.266
Hemoglobin ≥12 1911 49 % 235 12 % .000 Ref.
Hemoglobin 10-11 1307 34 % 243 19 % .000 1.664 1.404 1.972
Hemoglobin 9-10 380 10 % 99 26 % .000 2.819 2.222 3.577
Hemoglobin <9 269 7 % 95 35 % .000 5.090 3.899 6.644
Hemoglobin Missing 9 2 22 %
Albumin (g/dL) 3.4-4 513 13 % 21 4 % .000
Albumin (g/dL) <2 347 9 % 171 49 % .000 22.76 14.018 36.963
Albumin (g/dL) 2-3 1668 43 % 313 19 % .000 5.41 3.438 8.519
Albumin (g/dL) 3-3.4 721 19 % 55 8 % .012 1.93 1.155 3.242
Albumin (g/dL) Missing 627 16 % 114 18 % .000 5.21 3.217 8.427
Sodium (mmol/L) ≤130 412 11 % 76 18 % .000 1.00
Sodium (mmol/L) 130-150 3366 87 % 543 16 % .231 0.85 .652 1.109
Sodium (mmol/L) ≥150 97 3 % 55 57 % .000 5.79 3.609 9.287
Sodium(mmol/L) Missing 1 0 0 %
WBC (103/μL) 4≤≤12 1816 47 % 259 14 % .000 Ref.
WBC (103/μL) <4 144 4 % 27 19 % .007 1.668 1.150 2.421
WBC (103/μL) >12 1907 49 % 386 20 % .000 1.529 1.315 1.777
WBC (103/μL) Missing 9 2 22 %
Hematocrit (%) ≥30 3268 85 % 496 15 % Ref.
Hematocrit (%) <30 599 15 % 176 29 % .000 2.735 2.280 3.280
Hematocrit (%) Missing 9 2 22 %
RDW (%) ≤15 1958 59 % 242 12 % 1.00
RDW (%) >15 1373 41 % 348 25 % .000 2.41 2.008 2.886
RDW (%) Missing 545 84 15 %
GFR (ml/min) ≤90 852 22 % 106 12.4 % .000 1.00
GFR (ml/min) 60-90 1227 32 % 149 12.1 % .839 0.97 .746 1.269
GFR (ml/min) 30-60 1332 34 % 260 19.5 % .000 1.71 1.337 2.180
GFR (ml/min) 15-30 369 10 % 130 35.2 % .000 3.83 2.850 5.141
GFR (ml/min) <15 96 2 % 29 30.2 % .000 3.05 1.883 4.927
Phosphorus (mg/dL) 2.5-4.49 2790 72 % 415 14.9 % .000 1.00
Phosphorus (mg/dL) ≤2.49 643 17 % 91 14.2 % .641 0.94 .738 1.205
Phosphorus (mg/dL) ≥4.5 443 11 % 168 37.9 % .000 3.50 2.810 4.350
Phosphorus (mg/dL) 1.51-3.9 3004 78 % 396 13.2 % .000 1.00
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retrieved from the database of our hospital and the ministry
of health. Exclusion criteria included age under 18 years,
transfer from another hospital, hospitalization during
30 days prior to admission, hospital-acquired pneumonia
(defined as pneumonia which was diagnosed more than
48 hours after admission) or partial antibiotic treatment
before hospitalization.
The following data were retrieved from the electronic
medical records of the patients:
(1) Malignancies: solid tumors and hematologic malig-
nancies. (2) Pulmonary diseases: bronchial asthma, chronic
obstructive lung disease, interstitial lung disease, bronchiec-
tasis, permanent tracheostomy, past history of thoracic
radiotherapy, previous episode of pneumonia, and previous
or current active smoker. (3) Immune suppression condi-
tions: current chronic corticosteroid treatment, current or
recent chemotherapy treatment, carrier of HIV, primary
immune deficiency, history of bone marrow transplant-
ation. (4) Cardiovascular diseases including patients with
decompensated heart failure. (5) Chronic kidney disease
including patients on dialysis. (6) Diabetes mellitus. (7)
Liver cirrhosis. (8) Prior neurologic damage. (9) Chronic
alcohol use. (10) Intravenous drug abuse. (11) Nursing
house residents. The vital signs including heart rate, systolic
blood pressure, respiratory rate, oxygen saturation and
temperature were recorded on admission. The Charlson’s
comorbidity index was calculated based on the data
collected. The Charlson’s comorbidity index is a score that
predicts the ten-year mortality for a patient who may have
a range of comorbid conditions, (a total of 22 conditions),
while each condition is assigned a score of 1, 2, 3, or 6,
depending on the risk of dying associated with each condi-
tion. Scores are summed to provide a total score to predict
mortality [23].
Laboratory variables on admission
Serum glucose, serum creatinine, sodium, hemoglobin,
white blood count, Red blood cell Distribution width
(RDW), pH, calcium, phosphorus, bicarbonate, partial
pressure of CO2, lactate, blood urea nitrogen (BUN), and
serum albumin were measured on admission.
Hemoglobin levels, mean corpuscular volume and RDW
were measured on admission, using the Advia 120
Hematology Analyzer (Siemens Healthcare Diagnostics
Deerfield, Illinois, USA). Glucose, BUN and creatinine
levels were measured using the “Dimension” (Siemens
Healthcare Diagnostics Deerfield, Illinois, USA). The nor-
mal serum inorganic phosphorus range in the Rambam
Health Care Campus laboratory is 2.5-4.5 mg/dl. Hypopho-
sphatemia is defined as levels below 2.5 mg/d; whereas,
levels above 4.5 mg/dl defines hyperphoshphatemia.
Statistical analysis
Bivariate logistic regression analysis was used for the
calculation of the odds ratios (OR) with 95 % Confidence
Interval (CI) and P values in bivariate analysis to identify
association between patient’s characteristic and 30-day
mortality. Multivariate forward stepwise logistic regression
was performed to assess the relation between patient’s
characteristics: co-morbidities, laboratory results, and 30-
day mortality.
Variables were selected as candidates for the multivariate
analysis on the basis of the level of significance of the bi-
variate association with 30-day mortality (P < 0.1). Notably,
there was no predilection in choosing serum phosphorus or
any other variable in the statistical model.
The area under curve (AUC) was used as a measure of
model of discrimination. The calibration of the prediction
equation was assessed by comparing the observed and
expected numbers of 30-day mortality. The Hosmer-
Lemeshow goodness-of-fit statistic was calculated. We
calculated the Spearman’s rank correlation coefficient to
try to find out any correlation between variables that were
found positive in the multivariate analysis. Two-tailed P
values of 0.05 or less were considered as statistically
significant. All statistical analyses were performed using
SPSS (Statistics Products Solutions Services; Armonk,
New York, USA) 21.0 software for Windows; Redmond,
Washington, USA.
The Rambam Hospital Institutional Review Board ap-
proved the study. The approval number is 0515-12-RMB.
The need for informed consent was waived.
Results
Of the 5608 patients who were diagnosed with CAP in
Rambam Health Care Campus between January 1, 2006
and December 31, 2012; 3876 patients had serum inor-
ganic phosphorus levels were available within the first
24 hours of admission, and subsequently constituted our
cohort. Of these 3876 patients, 57 % were males with
median age of 69.6 years. The 30-day mortality was 17 %
(n = 674). As shown in Table 1, the 30-day mortality was
Table 2 Bivariate analysis of laboratory parameters associated with 30-day mortality (Continued)
Phosphorus (mg/dL) ≤1.5 62 2 % 24 38.7 % .000 4.16 2.468 7.009
Phosphorus (mg/dL) 4-4.49 367 9 % 86 23.4 % .000 2.02 1.548 2.624
Phosphorus (mg/dL) ≥4.5 443 11 % 168 37.9 % .000 4.02 3.232 5.009
Abbreviations: OR Odds Ratio, CI Confidence Interval, Ref. Reference, BUN Blood Urea Nitrogen, WBC White Blood Cells, RDW Red Blood Cell Distribution Width,
GFR Glomerular Filtration Rate
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not significantly different between men and women. As
well, the 30-day mortality each year was similar through-
out the study period.
Factors associated with 30-day mortality
As depicted in Table 1; 674 patients died within 30 days.
Patients who died were older and had higher Charlson’s
score reflecting more comorbid conditions. The year of
diagnosis and inclusion did not influence the rate of 30-day
mortality.
Table 2 shows the association between different labora-
tory parameters and 30-day mortality. When serum
phosphorus levels were examined according to the normal
laboratory range of our institution, that is, between 2.5
and 4.5 mg/dl and levels below 2.5 mg/dl representing
hypophosphatemia and levels above 4.5 mg/dl represent-
ing hyperphosphatemia; only hyperphosphatemia, but not
hypophosphatemia, was associated with increased mor-
tality risk with odds ratio (OR), 95 % confidence inter-
val (CI) and P value as follows: OR-3.5 (95 % CI 2.81-4.35,
P < 0.0001). According to the ROC curve, cutoff levels of
1.51and 3.9 mg/dl were associated with significant change
in specificity (Fig. 1). Therefore, we used levels between
1.51 and 3.9 as our new reference . Accordingly, the 30-
day mortality rate was 13.2 % and increased to 38.7 %
30-day mortality rate with OR-4.16 (95 % CI 2.468-7.009,
P <0.0001) in patient with levels ≤ 1.5 mg/dl. Notably,
levels between 4-4.49 mg/dl and ≥ 4.5 mg/dl were associ-
ated with 23.4 % and 37.9 % 30-day mortality rate with
OR-2.02 (95 % CI 1.548-2.6.24, P < 0.0001) and OR-4.02
(95 % CI 3.232-5.009, P < 0.0001), respectively. Figure 2
shows the correlation between different serum phos-
phorus levels and 30-day mortality.
Relationship between Glomerular Filtration Rate (GFR),
Phosphorus and Mortality
As shown in Fig. 3, the predictive value of serum phos-
phorus levels on CAP outcome was maintained even after
adjustment for GFR. Through all levels of GFR, hypopho-
sphatemia and hyperphosphatemia were associated with
increased mortality rates.
Relationship between CURB-65, Phosphorus and Mortality
The predictive value of serum phosphorus levels on CAP
outcome was maintained after adjustment for CURB-65
score. While obviously higher CURB-65 score was
ROC=0.613 95% CI 0.59-0.64
Fig. 1 Serum Phosphrus ROC Curve
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associated with excess of mortality rates, severe hypopho-
sphatemia and hyperphosphatemia were further associated
with increased mortality rates for each CURB-65 score
(Fig. 4).
Relationship between Blood Urea Nitrogen (BUN),
Phosphorus and Mortality
As shown in Fig. 5, the predictive value of serum phos-
phorus levels on CAP outcome was maintained even after
adjustment for BUN. Through all levels of BUN, hypopho-
sphatemia and hyperphosphatemia were associated with
increased mortality rates.
Multivariate analysis of factors associated with 30-day
mortality
As shown in Table 3, the following factors were associated
with higher rates of 30-day mortality: sodium >150 meq/l,
RDW> 15, low albumin levels (<2) and age >80 years.
Increasing CURB-65 scores were associated with higher
mortality. Whenever serum phosphorus levels were added
to the model, severe hypophosphtemia (<1.5 mg/dl), levels
between 4 and 4.5 mg/dl, and especially levels above
4.5 mg/dl were associated with significant mortality. The
addition of serum phosphorus levels to the model
improved AUC/ROC curve from 0.747 (95 % CI = 0.726-
0.769) to 0.764 (95 % CI = 0.743-0.786). The Hosmer-
Lemeshow goodness-of-fit statistic was not statistically
significant (p = 0.77) indicating little departure and a
perfect fit in both models.
In order to check for a possible correlation between
serum phosphorus levels and other parameters, the sper-
man’s correlation coefficient was calculated; however no
significant correlation was found (Table 4).
Discussion
In this study, we examined the role of serum phosphorus
levels as a predictor of 30-day mortality in patients admit-
ted to medical wards because of CAP. Our study demon-
strated that serum phosphorus level obtained within
24 hours from admission can predict 30-day mortality,
with levels below 1.5 mg/dl and levels above 4.5 mg/dl
being associated with increased mortality levels. It is
remarkable to note that when we followed the conven-
tional international definitions for hyperphosphatemia
(>4.5 mg/dl) and hypophosphatemia (<2.5 mg/dl), only
Fig. 3 The relationship between GFR, Phosphorus and Mortality
Fig. 2 30-day mortality according to phosphorus levels
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hyperphosphatemia was associated with increased mortal-
ity. However, when levels between 1.5-3.9 mg/dl constituted
our reference group with 30-day mortality of 13.2 %; levels
below 1.5 mg/dl and above 4.5 mg/dl were both associated
with increased 30-days mortality, 38.7 % and 37.9 %,
respectively. Notably, even levels between 4-4.49 mg/dl,
that are considered to be normal according to labora-
tory standards, were associated with 23.4 % 30-day
mortality rates.
Phosphorus, as an essential component in the ATP
molecule, plays a central role in the energy production.
Therefore, depleted phosphorus stores, reflected by
hypophosphatemia, might lead to insufficient and re-
duced ATP production which subsequently impairs sev-
eral vital systemic functions including the immune
system and the ability of the lungs to clear edema [24].
Craddock et al have shown that severe hypophosphate-
mia causes acquired phagocyte dysfunction reflected by
defected chemotaxis, phagocytosis and bactericidal ac-
tivity [21].
Hypophosphatemia in the setting of acute infectious
illness such as CAP might have several etiologies, includ-
ing refeeding, insulin therapy, acute respiratory alkalosis,
inadequate intake, decreased phosphorus absorption
Fig. 5 the relationship between BUN, Phosphorus and Mortality
Fig. 4 The relationship between CURB-65, Phosphorus and Mortality
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(eg. anti-acids), and the use of medications (eg. methylpred-
nisolone, epinephrine, terbutaline, and theophylline)
[13–20]. On the contrary, the causes of hyperphospha-
temia in the acute setting of CAP are very few and usu-
ally include acute renal failure, phosphorus-containing
medications and lactic or ketoacidosis. Di Marco et al
have reported that high phosphorus levels can impair
endothelial cell function at several levels including induc-
tion of sustained stiffening, increased apoptosis, impaired
angiogenesis, impaired cell migration, downregulation of
extracellular annexin II expression and shedding of endo-
thelial microparticles [25]. Altogether, this suggests that
hyperphosphatemia can interfere with normal function of
the immune system.
Our study demonstrated that increased serum creatinine
and urea levels were also associated with increased 30-day
mortality, therefore, we aimed to examine whether the
association between serum phosphorus levels and 30-day
Table 4 Spearman’s Rank Correlation coefficient parameters
% of Pts with
P≤ 1.5
% of Pts with
P 1.51-2.49
% of Pts with
P 2.5-3.99
% of Pts with
P 4-4.49
% of Pts with
P ≥4.5
SPEARMAN
Age (years) <40 271 4 20 62 7 7 0.078
40-49 209 2 15 65 11 7
50-59 356 1 21 58 8 11
60-69 579 1 16 62 9 11
70-79 1016 1 15 62 9 13
≥80 1445 2 12 64 10 12
Albumin (g/dL) 3.4-4 513 0 12 65 11 12 0.040
<2 347 4 17 50 10 18
2-3 1668 1 15 62 8 12
3-3.4 721 1 14 66 10 9
Missing 627 2 17 64 10 8
Sodium (mmol/L) ≤130 412 2 19 61 7 12 0.049
130-150 3366 2 15 63 10 11
≥150 97 1 12 55 13 19
Missing 1 0 100 0 0 0
RDW (%) ≤15 1958 2 17 65 8 8 0.144
>15 1373 1 11 59 11 17
Missing 545 2 17 64 10 7
60-90 1227 2 18 67 8 5
30-60 1332 1 14 63 10 12
15-30 369 2 7 44 14 33
<15 96 0 5 25 11 58
CURB-65 0 589 1 20 66 8 6
1 881 2 16 67 8 6
2 1286 1 13 64 10 12
3 1120 2 13 56 11 18
Abbreviations: RDW Red Blood Cell Distribution Width
Table 3 Multivariate analysis of factors associated with 30-day
mortality
Parameter Value P-value Adjusted OR 95 % CI
Lower Upper
CURB-65 ≤1 .000 Ref.
2 .017 1.4 1.1 1.9
≥3 .000 3.5 2.6 4.7
Albumin (g/dL) <2 .000 3.8 2.9 5.0
RDW(%) >15 .000 1.6 1.3 1.9
Sodium (mmol/L) ≥150 .000 3.1 2.0 4.9
Age(years) ≥80 .000 1.6 1.3 2.0
Phosphorus (mg/dL) 1.51-3.9 .000 Ref.
≤1.5 .000 3.8 2.1 6.8
4-4.49 .001 1.7 1.3 2.3
≥4.5 .000 3.0 2.3 3.8
Abbreviations: OR Odds Ratio, CI Confidence Interval, Ref. Reference,
RDW Red Blood Cell Distribution Width
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mortality was related to renal failure. We reexamined the
association between serum phosphorus levels and 30-day
mortality after adjustment for GFR levels. As shown in
Fig. 2, even after adjustment for GFR levels, serum phos-
phorus levels below 1.5 mg/dl and levels above 4 mg/dl
were associated with increased 30-day mortality at each
GFR subgroup. This indicates that serum phosphorus levels
were associated with 30-day mortality regardless of GFR,
creatinine or urea levels.
We also adjusted for CURB-65 score to evaluate whether
serum phosphorus levels have an additional prognostic
value. We showed that the prognostic value of serum phos-
phorus levels below 1.5 mg/dl and levels above 4 mg/dl was
maintained at each CURB-65 score. Therefore, in levels
below 1.5 mg/dl, intravenous treatment of elemental phos-
phuros should be strongly considered.
In this study we reproduced our previous findings show-
ing the elevated RDW is associated with increased mortality
in patients with Community acquired pneumonia [26].
Our study has several limitations. The first is the retro-
spective design of the study. Secondly, data regarding the
exact cause of 30-day mortality was not available in all cases
and unfortunately, chest radiography appearance on admis-
sion was not included among the parameters examined.
The third limitation was that not all patients admitted with
CAP had serum phosphorus levels within 24 hours from
admission. This may, in fact, reflect the fact that serum
phosphorus levels were available for the more severe
patients. This fact is consistent with our finding that the
predictive value of serum phosphorus levels was greater in
higher CURB-65 scores. Because of the retrospective nature
of the study, data regarding vitamin D levels, Parathyroid
hormone, Fibroblast growth factor-23 (FGF-23) levels and
the urinary phosphorus excretion were not available. These
vitamins and hormones are known to play a central role in
the hemostasis of serum phosphorus, and might subse-
quently affect 30-day mortality. A fourth limitation was the
lack exact information about antibiotic treatment pre
admission; therefore, unfortunately, these patients were
excluded.
Conclusions
Abnormal serum phosphorus levels on admission are
associated with increased 30-mortality rates among adult
patients hospitalized with CAP. The predictive value of
phosphorus levels is maintained even after adjustment to
GFR and CURB-65 levels.. We believe there is a real need
to examine the prognostic predictive value of serum phos-
phorus levels on admission on 30-day mortality in patients
with community acquired pneumonia prospectively, along
with vitamin D levels, Parathyroid hormone, Fibroblast
growth factor-23 (FGF-23) levels and the urinary phos-
phorus excretion.
Abbreviations
CAP: Community acquired pneumonia; OR: Odds ratio; CI: Confidence
interval; RDW: Red blood cell distribution width; GFR: Glomerular filtration
rate; BUN: Blood urea nitrogen.
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